What about adults having TMA on kidney biopsy secondary to antiphospholipid syndrome, would you still need to look at complement mediated reasons or primary APS is enough and only supportive care is indicated along with PEX. Would eculizimab be beneficial in such patients?
Mutations in C3 account for about 2-10% of patients with aHUS and are usually heterozygous in nature [24]. Disease-causing mutations in C3 are a gain of function mutation as the mutant C3 contributes to increased formation of C3 convertase by binding to CFB . The mutated C3 is not amenable to regulation by MCP, which normally serves to inactivate C3b. In approximately 80% of patients, C3 levels are decreased
Thank you so much Mam. You made this so simple and easy to understand 🙏
Difference Between ITP,HUS,TTP and HSP..How to remember these confusion?
Mam your notes available?
What about adults having TMA on kidney biopsy secondary to antiphospholipid syndrome, would you still need to look at complement mediated reasons or primary APS is enough and only supportive care is indicated along with PEX. Would eculizimab be beneficial in such patients?
It’s great work mam .. thanks
well presented Madam,
maam do every aHUS pat need plex even if clinically pat resolving in the way that plat count and aki resolving and dialysis was not even needed ?
Very well explained Mam
Thank you👍
do we do Direct coombs test in HUS regularly
Hemolytic Uremic Syndrome (HUS) found for me after delivering my first child is that safe to plan another pregnancy? he is 5 yrs now he is healthy
mam...we want detailed teachings on ADHD..
leukemia in children..
Nephrotic syndrome
post encephalitis sequeles
tubercular meningitis
thalasemia
sickle cell anaemia
megaloblastic anaemia..
That's a long list doctor. Will try my best to teach topics one by one
Fabulous explanation mam👌
Mam...kindly do video on KAWASAKI disaese
Will try doctor
Maam what is the role of c3 c4 levels in hus...
Mutations in C3 account for about 2-10% of patients with aHUS and are usually heterozygous in nature [24]. Disease-causing mutations in C3 are a gain of function mutation as the mutant C3 contributes to increased formation of C3 convertase by binding to CFB . The mutated C3 is not amenable to regulation by MCP, which normally serves to inactivate C3b. In approximately 80% of patients, C3 levels are decreased
Mam superb teaching 🙏🙏🙏 really awesome.... Mam, Please teach us daily, upto our dnb exams mam..🙏
I will try my best
@@pediatrictakesbydr.pavitra9813 👌👌👌👌👌
Excellent class mam
Thank you
Mam nice presentation can u teach dysexia
hello maam please teach leukemia and non Hodgkins lymphoma
Tq
Thank u mam